405 filings
Page 5 of 21
8-K
6w99biakphq
30 Dec 22
Termination of a Material Definitive Agreement
5:00pm
D
g9q 2hds73jd2owygka0
29 Dec 22
$30.00 mm in equity, sold $7.50 mm, 17 investors
3:12pm
S-8
wem7ugl80voye
22 Dec 22
Registration of securities for employees
5:37pm
8-K
bdji jjcn5
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K/A
ti7xf
16 Dec 22
Other Events
2:58pm
8-K
9khl3llct
15 Dec 22
Completion of Acquisition or Disposition of Assets
6:11am
8-K
1ebp5z8z7r
13 Dec 22
Submission of Matters to a Vote of Security Holders
4:02pm
425
gm6ekdmmggujy
6 Dec 22
Business combination disclosure
4:04pm
8-K
daxt8wuv
6 Dec 22
Regulation FD Disclosure
4:02pm
425
xr30zbve
5 Dec 22
Business combination disclosure
9:28am
8-K
aa47wa4g 1njvrmhk
5 Dec 22
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
9:27am
424B3
6m0ketkg1lead
5 Dec 22
Prospectus supplement
9:22am
425
4x85i4w nbrn9rbg
1 Dec 22
Business combination disclosure
4:04pm
8-K
9udu2 s2ik7x3edl27wk
1 Dec 22
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
4:01pm
425
h9z88r7r ap
29 Nov 22
Business combination disclosure
4:03pm
8-K
d7886f
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
425
f105ruvy
28 Nov 22
Business combination disclosure
4:03pm
8-K
cya2c5p1
28 Nov 22
Regulation FD Disclosure
4:01pm
SEC STAFF
kvf17v3 w15
17 Nov 22
SEC staff action: Order
12:00am
425
xly118gwpu
15 Nov 22
Business combination disclosure
4:03pm